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We have begun to explore the downstream signaling pathways of receptor protein tyrosine phosphatases
(RPTPs) that control axon guidance decisions in the Drosophila central nervous system. We have focused our
studies on the adhesion molecule-like gp150 protein, which binds directly to and is an in vitro substrate for the
RPTP DPTP10D. Here we show that gp150 and DPTP10D form stable complexes in Drosophila Schneider 2
(S2) cells and in wild-type larval tissue. We also demonstrate that the DPTP10D cytoplasmic domain is
sufficient to confer binding to gp150. gp150 has a short cytoplasmic domain containing four tyrosines, all found
within sequences similar to immunoreceptor family tyrosine-based activation motifs (ITAMs). We demonstrate
that gp150 is tyrosine phosphorylated in wild-type larvae. In S2 cells, gp150 becomes tyrosine phosphorylated
following incubation with PTP inhibitors or upon coexpression of the Dsrc tyrosine kinase. Phosphorylated
Dsrc and an unknown 40-kDa phosphoprotein form stable complexes with gp150, thereby implicating them in
a putative gp150 signaling pathway. When coexpressed with gp150, either full-length DPTP10D or its cyto-
plasmic domain mediates gp150 dephosphorylation whereas a catalytically inactive DPTP10D cytoplasmic
domain does not. The neural RPTP DPTP99A can also induce gp150 dephosphorylation but does not coim-
munoprecipitate with gp150. Taken together, the results suggest that gp150 transduces signals via phosphor-
ylation of its ITAM-like elements. Phosphotyrosines on gp150 might function as binding sites for downstream
signaling molecules, thereby initiating a signaling cascade that could be modulated in vivo by RPTPs such as
DPTP10D.
Protein phosphorylation on tyrosine residues is regulated by
the activities of protein tyrosine kinases (PTKs) and protein
tyrosine phosphatases (PTPs). Like PTKs, PTPs are a large
family of multidomain proteins that exist in both cytoplasmic
and transmembrane (receptor) forms. Many receptor PTPs
(RPTPs) have extracellular regions that include tandemly ar-
ranged fibronectin type III repeats alone or in conjunction with
immunoglobulin-like domains. This organization resembles
that of some cell adhesion molecules, suggesting that RPTPs
could participate in intercellular communication. Of note, the
RPTPs PTPm and PTPk mediate homophilic adhesion in ag-
gregation assays (3, 35, 50) and RPTPb (PTPz) interacts with
several neural cell adhesion molecules (1a, 27, 31, 32). Al-
though the significance of these interactions on catalytic activ-
ity is not known, engagement of their extracellular domains
could modulate phosphatase activity and/or colocalize RPTPs
with substrates (reviewed in reference 12).
Of the five identified Drosophila RPTPs, four (DPTP10D,
DPTP69D, DPTP99A, and DLAR) are selectively expressed
on central nervous system (CNS) axons (9, 18, 44, 47) and
contribute to growth cone guidance during nervous system
development. Genetic evidence shows that DPTP69D,
DPTP99A, and DLAR control specific motoneuron growth
cone guidance decisions in the embryonic neuromuscular sys-
tem (8, 22). These RPTPs control defasciculation of axons
from common pathways and can also regulate the entry of
these axons into synaptic target regions (7). Genetic evidence
also implicates DPTP10D and DPTP69D in the guidance of
interneuronal axons within the CNS (43a). RPTPs are also
expressed on neuronal growth cones and processes in verte-
brates (2, 41, 42), suggesting that their functions in controlling
axon guidance might be conserved between vertebrates and
arthropods.
To investigate the signaling pathway(s) through which Dro-
sophila neural RPTPs transmit intracellular messages, we ini-
tially designed an in vitro system to identify proteins that in-
teract with the cytoplasmic domain of DPTP10D. The
DPTP10D cytoplasmic region, which includes a single PTP
catalytic domain, was used as an affinity matrix to isolate pu-
tative substrates and/or downstream signaling proteins from
Drosophila primary neuronal and Schneider 2 (S2) cell lysates.
A transmembrane glycoprotein (gp150) which binds to the
DPTP10D catalytic domain was identified by this assay and
characterized as an in vitro substrate for DPTP10D (45). Of
note, the expression pattern of gp150 mRNA overlaps tempo-
rally with that of DPTP10D mRNA during embryogenesis.
Furthermore, gp150 mRNA is expressed throughout the em-
bryo, with the highest levels at segmental boundaries and along
the CNS midline. Since DPTP10D mRNA and protein are
expressed in most CNS neurons (44, 47), it is likely that gp150
and DPTP10D are coexpressed in the embryonic CNS.
The extracellular domain of gp150 contains 18 leucine-rich
repeat (LRR) sequences. The presence of LRRs in gp150 is
suggestive in that a number of Drosophila adhesion/signaling
molecules, including chaoptin, connectin, and Toll, also con-
tain multiple LRRs in their extracellular domains (19, 29, 33).
The short (62-amino-acid) predicted cytoplasmic domain of
gp150 includes four tyrosine residues arranged in motifs sim-
ilar to vertebrate immunoreceptor family tyrosine-based acti-
vation motifs (ITAMs) (5). ITAMs such as those of the T-cell
receptor (TCR) z chain are rapidly phosphorylated following
receptor ligation, and these phosphorylated ITAMS bind to
downstream effector proteins that contain Src homology 2
(SH2) domains (20). Phosphorylated ITAMs are also in vitro
substrates for the RPTP CD45, which is required for normal
TCR signaling (14).
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Our laboratory has previously shown that the ITAM-like
elements of gp150 can be phosphorylated in vitro and that
these phosphorylated tyrosine residues are in vitro substrates
for the bacterially expressed DPTP10D catalytic domain (45).
These results suggested that gp150, like vertebrate immunore-
ceptors, might become phosphorylated in vivo and conse-
quently interact with phosphotyrosine-binding downstream sig-
naling molecules. Moreover, DPTP10D and perhaps other
PTPs could modulate the levels of gp150 phosphorylation,
thereby affecting potential gp150-mediated signaling pathways.
In this study, we investigated interactions between
DPTP10D and gp150 in lysates derived from larval tissue and
from transfected Drosophila S2 cells. We show that gp150 and
DPTP10D form stable complexes in these cellular contexts and
that the cytoplasmic domain is sufficient to confer gp150 bind-
ing. We also show that gp150 derived from larval tissue is
tyrosine phosphorylated and that gp150 can be inducibly phos-
phorylated in S2 cells. In addition to forming stable complexes
with gp150, DPTP10D dephosphorylates gp150 in a concen-
tration-dependent manner in S2 cells. In summary, these re-
sults support the hypothesis that DPTP10D regulates gp150
signaling in vivo.
MATERIALS AND METHODS
Plasmid construction. An epitope-tagged full-length gp150 was generated by
a “bridge PCR” procedure in which the 39 terminus of gp150 DNA was fused in
frame to six tandem myc epitope tags. The bridge PCR product was sequenced
by the Caltech Sequencing Facility to confirm accurate amplification of the two
fused DNAs. The gp150myc DNA was then subcloned into the metallothionein
promoter vector pRMHa3 (4), and this construct was designated gp150myc-
pRM. Full-length, untagged gp150, DPTP10D, DPTP99A, and DPTP69D
cDNAs were also subcloned into pRMHa3 and denoted gp150-pRM, DPTP10D-
pRM, DPTP99A-pRM, and DPTP69D-pRM, respectively. The 10Dwt-pRM
construct includes the DPTP10D cytoplasmic domain which has been modified
to include a Src myristylation sequence (34) at its N terminus (this sequence
should confer membrane association) and a single myc epitope at the 39 termi-
nus. 10D(C-S)-pRM is a derivative of 10Dwt-pRM, in which the essential cys-
teine (DPTP10D residue 1468) has been mutated to serine by standard proce-
dures. The Drosophila tyrosine kinase constructs pPac/Dsrc, pPac/Dabl, and
pPac/Dfer have been described previously (16). Enzymes were obtained from
Boehringer Mannheim Biochemical Co. and New England Biolabs.
gp150 MAb generation. A BalI fragment encoding amino acids 250 to 746 of
gp150 was subcloned into a glutatione S-transferase vector, and the resulting
fusion was protein purified with glutathione-Sepharose. Monoclonal antibodies
(MAbs) against this fusion protein were generated at the Caltech Monoclonal
Antibody Facility and screened based on their ability to recognize gp150 on
Western blots and to immunoprecipitate native gp150 from cell lysates. The
MAb 8C1.1B4, which worked well for both immunoprecipitations and immuno-
blotting, was used in this study.
Larval CNS and imaginal disc dissections and lysis. Wild-type third-instar
larvae were Oregon R. In the experiment of Fig. 2B, lane 1, the larvae were from
a cross between females bearing an X-linked GAL4 source (denoted C155; the
insertion is probably in the elav gene [25] that is selectively expressed in differ-
entiated neurons) and males homozygous for an autosomal insertion of a P
element vector containing an upstream activation sequence-driven cDNA en-
coding the “long” spliced form of DPTP10D (47). This line was generated and
characterized by Bahri et al. (1). It overexpresses DPTP10D in embryonic and
larval neurons. DPTP10D overexpression does not cause any detectable pheno-
types in embryos or adults. The CNS and imaginal discs were dissected away
from the gut, salivary glands, and other tissues and washed three times in ice-cold
13 phosphate-buffered saline (PBS). For each sample, CNS or disc isolates from
30 larvae were lysed in 500 ml of ice-cold lysis buffer (125 mM NaCl, 100 mM
Tris-Cl [pH 7.5], 0.2% Triton X-100) supplemented with 600 mM phenylmeth-
ylsulfonyl fluoride (PMSF), 2 mg of aprotinin per ml, 10 mg of leupeptin per ml,
and 1 mM benzamidine. The tissue was then homogenized in microcentrifuge
tubes by ;10 strokes with a plastic pestle, and the macerated tissue was incu-
bated on ice for an additional 10 min. Nuclei and insoluble membrane compo-
nents were then removed by 10 min of centrifugation (Eppendorf microcentri-
fuge 5415 rotor) at 13,200 rpm and 4°C. For immunoprecipitations, either 800 ml
of 8C1.1B4 anti-gp150 MAb supernatant or an equivalent amount of purified
mouse immunoglobulin G (IgG) (Sigma Immunochemicals) was incubated with
the clarified lysate for .2 h and immune complexes were isolated and analyzed
as described below.
S2 cell transfection, induction, activation treatments, and lysis. S2 cells (36)
were maintained in Schneider’s medium supplemented with 100 U of penicillin
per ml, 100 mg of streptomycin per ml, 0.25 mg of amphotericin B (Life Tech-
nologies) per ml, and 10% heat inactivated fetal calf serum (Gemini, Inc.). Cells
were grown at 25°C under standard atmospheric conditions. S2 cells were tran-
siently transfected by calcium phosphate-mediated DNA transfer (38). Briefly,
107 cells in 7 ml of growth medium were seeded in 10-cm plates and expanded
overnight. The cells were then transfected for 15 to 18 h by the addition of 2 ml
of DNA-calcium phosphate coprecipitate mix (which included 0.5 to 20 mg of
plasmid DNA), washed in 13 PBS, and resuspended in growth medium. CuSO4
(0.3 mM) was added to the cells for ;24 h to induce the MT promoter to drive
expression from the transfected plasmids. To induce phosphorylation of
gp150myc, transfected cells were treated as follows (incubation times listed in
parentheses): 2 mM Na3VO4 and/or 3 mM H2O2 (35 min), 10 mg of insulin per
ml (Collaborative Research; 5 min), or 200 nM calcium ionophore A23187
(Sigma Immunochemicals; 5 min). The cells were then harvested, washed with
13 PBS, and lysed in 450 ml of ice-cold lysis buffer (125 mM NaCl, 100 mM
Tris-Cl [pH 7.5], 0.2% Triton X-100, 2 mM Na3VO4, 25 mM NaF, 600 mM
phenylmethylfulfonyl fluoride, 2 mg of aprotinin per ml). Nuclei and insoluble
membrane components were then removed by centrifugation.
Immunoprecipitations and Western blot analysis. For immunoprecipitations,
lysates (450 ml) were incubated with 1 to 3 mg of anti-myc mouse MAbs (On-
cogene Science, Inc.), 600 ml of 8C1.1B4 anti-gp150 MAb supernatants, or 2.4 mg
of affinity-purified anti-Enabled (Ena) rabbit antiserum for .2 h at 4°C. The
purified anti-Ena antiserum, which was generated against a carboxyl-terminal
Ena fusion protein (16), was generously provided by A. R. Comer and F. M.
Hoffmann (McArdle Laboratory for Cancer Research and Laboratory of Genet-
ics, University of Wisconsin Medical School). Immune complexes were isolated
by binding to protein G plus protein A-agarose beads (Oncogene Science, Inc.)
followed by two cycles of centrifugation and lysis buffer washes. The washed
immunoprecipitates were then boiled in sodium dodecyl sulfate sample buffer,
resolved on sodium dodecyl sulfate–9% polyacrylamide gels, and transferred to
polyvinylidene difluoride membranes (Immobilon-P; Millipore Corp.). The fil-
ters were blocked with either 3% bovine serum albumin (for anti-phosphoty-
rosine immunoblots) or 1 to 5% Blotto in TBST (25 mM Tris-Cl [pH 7.4], 137
mM NaCl, 0.2% Tween 20). Immunoblots were performed with anti-myc MAbs
(0.1 mg/ml), anti-DPTP10D mouse MAbs 45E10 and 37F5 (1:5 dilution), anti-
DPTP69D mouse MAb 3F11 (1:5 dilution), 4G10 anti-phosphotyrosine mouse
MAbs (1 mg/ml; Upstate Biotechnology Inc.), or anti-gp150 MAb 8C1.1B4 (1:5
dilution). The filters were then washed with TBST, incubated with alkaline
phosphatase-conjugated goat anti-mouse antibodies (Jackson Immunoresearch),
and developed to detect phosphatase activity. The immunoblots were scanned to
quantitate the intensity of different protein bands by using NIH 1.52 software.
For Dsrc immunoblots, the filters were incubated sequentially with anti-Dsrc rat
polyclonal antiserum (1:1,000 dilution [23]) and horseradish peroxidase conju-
gated goat anti-rat antibodies (Santa Cruz Biotechnology) and developed by
enhanced chemiluminescence (Amersham).
RESULTS
gp150 forms complexes with DPTP10D in S2 cells. To study
endogenous gp150, we first generated MAbs against the gp150
extracellular domain. MAb 8C1.1B4, which worked well for
both immunoprecipitations and immunoblotting, was used in
this study. Immunoblot analysis of anti-gp150 immunoprecipi-
tated with MAb 8C1.1B4 revealed that endogenous gp150 was
expressed in two forms in S2 cells, a 150-kDa species and a
180-kDa species (Fig. 1A, lane 1). Upon transfection of an
expression plasmid containing a full-length gp150 cDNA into
S2 cells, ;20-fold increases in the levels of both the 150- and
180-kDa species were observed (Fig. 1A, compare lanes 1 and
2), thereby confirming that both species were encoded by the
gp150 cDNA. Differential posttranslational modification is a
likely explanation for the presence of these two gp150 species.
Since gp150 was originally identified as a protein that bound
in vitro to the DPTP10D cytoplasmic domain (45), we sought
to determine if gp150 and DPTP10D could interact in cells. To
this end, we transfected S2 cells with an expression plasmid
encoding the “long” form of DPTP10D (47), which migrates as
a tight doublet or a single band at ;210 kDa. We detected a
faint DPTP10D doublet in anti-gp150 immunoprecipitates de-
rived from cells expressing endogenous gp150 and high levels
of exogenous DPTP10D (Fig. 1A, lane 1), demonstrating that
overexpression of gp150 was not required to visualize this
interaction. The amount of coimmunoprecipitating DPTP10D
was greatly increased, however, in cells expressing high levels
of both exogenous gp150 and DPTP10D (lane 2). As shown in
lanes 3 and 4, equal amounts of DPTP10D protein were ex-
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pressed in the S2 cell lysates from which these gp150 immu-
noprecipitates (lanes 1 and 2) were isolated. These data dem-
onstrate that gp150 and DPTP10D form stable complexes in
Drosophila cells, thereby confirming and extending the results
of the original in vitro binding studies (45).
We also expressed a gp150 fusion protein (gp150myc) which
bears a myc epitope tag at its carboxyl terminus. gp150myc can
be efficiently immunoprecipitated with anti-myc antibodies and
distinguished from endogenous (untagged) gp150. The 210-
kDa DPTP10D band was also present in anti-myc immunopre-
cipitates derived from S2 cells coexpressing gp150myc and
DPTP10D (Fig. 1B, lanes 2 and 3). Interestingly, when we
induced tyrosine phosphorylation of gp150myc by treatment of
transfected cells with PTP inhibitors (see Fig. 3), we noted a
modest increase in the amount of coimmunoprecipitating
DPTP10D (Fig. 1B, compare lanes 2 and 3). The ability to
associate stably with gp150 is not a common feature of all
RPTPs, however, since coexpression of high levels of either
DPTP99A or DPTP69D did not result in the appearance of
detectable amounts of these RPTPs in anti-gp150 immunopre-
cipitates (unpublished results). Taken together, our data un-
derscore the selective ability of DPTP10D to form complexes
with gp150 in vivo.
We also evaluated the ability of the isolated DPTP10D cy-
toplasmic domain to form complexes with gp150 in S2 cells. To
this end, we coexpressed untagged gp150 together with myc-
tagged versions of either the wild-type cytoplasmic domain
(10Dwt) or the derivative cytoplasmic domain 10D(C-S) in
which the essential catalytic cysteine residue was mutated to a
serine. This mutation renders PTPs catalytically inactive, and
analogous mutations in the catalytic domains of other PTPs
have been shown to stabilize phosphatase-substrate interac-
tions (for a review, see reference 28). Immunoblot analysis of
anti-myc immunoprecipitates showed that the myc-tagged
DPTP10D cytoplasmic proteins 10Dwt and 10D(C-S) were
expressed at high levels in S2 cells (Fig. 1C, lanes 2 and 3). The
lower electrophoretic mobility of the 10D(C-S) protein than
that of 10Dwt is probably due to the presence of phosphory-
lated tyrosine residues in the mutant protein (unpublished
results).
Immunoblots of anti-myc immunoprecipitates probed with
anti-gp150 MAbs revealed that untagged gp150 formed com-
plexes with the 10D(C-S) mutant protein (Fig. 1C, lane 3). The
levels of coprecipitated gp150 were quite low, however, sug-
gesting that the extracellular domain of DPTP10D may
strengthen and/or stabilize the interaction. We could not de-
tect gp150 in anti-myc immunoprecipitates derived from cells
coexpressing 10Dwt and gp150 (lane 2). Although there was
some variability in the amount of gp150 expressed in the ly-
sates (lanes 4 to 6) from which these immunoprecipitates were
derived, anti-myc immunoprecipitates of the 10D(C-S) mutant
protein consistently included gp150 whereas those of 10Dwt
did not. These findings may reflect the recently described phe-
nomenon of PTP substrate trapping, in which mutations in the
catalytic domain of other PTPs stabilize their association with
substrates by inhibiting dissociation (13, 15; reviewed in refer-
ence 28). Taken together, our results demonstrate that the
cytoplasmic domain of DPTP10D is sufficient to confer stable
gp150 binding.
gp150 forms complexes with DPTP10D in larvae. To exam-
ine whether endogenous gp150 is associated with DPTP10D in
vivo, we analyzed gp150 immunoprecipitates derived from
wild-type third-instar larval CNS and imaginal disc lysates. As
shown in Fig. 2A (lane 2), immunoblotting gp150 immunopre-
cipitates with anti-gp150 MAbs revealed that a single 180-kDa
band was observed in larval tissue. This species of gp150 comi-
FIG. 1. gp150 forms complexes with DPTP10D in S2 cells. (A) Lysates from
transfected S2 cells expressing DPTP10D alone (lane 1) or with untagged gp150
(lane 2) were immunoprecipitated with anti-gp150 (a-gp150) antibodies and
processed for immunoblotting with either anti-DPTP10D (a-DPTP10D) (top) or
anti-gp150 (bottom) antibodies. Note that endogenous gp150 was expressed at
detectable levels in S2 cells (lane 1) and gp150 expression was augmented
following transfection of gp150-pRM (lane 2). The fuzzy upper band in each
anti-gp150 panel is the 180-kDa gp150 form. DPTP10D was observed in gp150
immunoprecipitates (ip) from lysates expressing endogenous (lane 1) and exog-
enous (lane 2) levels of untagged gp150. Total-cell lysates from transfected S2
cells expressing DPTP10D alone (lane 3) or with untagged gp150 (lane 4) were
processed for immunoblotting with anti-DPTP10D antibodies. DPTP10D ex-
pression levels were similar between these lysates and were therefore not affected
by coexpression of gp150. (B) Lysates from transfected S2 cells expressing myc-
tagged gp150 (gp150myc) alone (lane 1) or with DPTP10D (lanes 2 and 3) were
immunoprecipitated with anti-myc (a-myc) antibodies and processed for immu-
noblotting with either anti-DPTP10D (top) or anti-myc (bottom) antibodies.
DPTP10D was observed in gp150myc immunoprecipitates from cells that were
untreated (lane 2) or treated with Na3VO4 and H2O2 (lane 3). Note the increase
in the amount of DPTP10D coimmunoprecipitating with gp150myc in Na3VO4-
and H2O2-treated cells (compare lanes 2 and 3). gp150myc expression levels
were not altered by coexpression of DPTP10D. (C) Lysates from transfected S2
cells expressing untagged gp150 alone (lane 1) or with myc-tagged forms of either
the wild-type (lane 2) or mutant (lane 3) DPTP10D cytoplasmic domain were
immunoprecipitated with either anti-gp150 (lane 1) or anti-myc (lanes 2 and 3)
antibodies and processed for immunoblotting with either anti-gp150 (top) or
anti-myc (bottom) antibodies. Note that untagged gp150 coimmunoprecipitated
with mutant [10D(C-S); lane 3] but not wild-type (10Dwt; lane 2) protein. 10Dwt
and 10D(C-S) were expressed at similarly high levels (bottom). Although this
panel is overdeveloped to emphasize the lack of myc immunoreactivity in cells
that were not transfected with 10Dmyc constructs, other experiments done with
shorter development times reveal that the 10Dwt and 10D(C-S) bands are of
equivalent intensities. Total-cell lysates from transfected S2 cells expressing
untagged gp150 alone (lane 4) or with myc-tagged forms of either the wild-type
(lane 5) or mutant (lane 6) DPTP10D cytoplasmic domain were processed for
immunoblotting with anti-gp150 antibodies.
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grates with the higher-molecular-mass form seen in S2 cells
(Fig. 1). When the gp150 immunoprecipitates were probed
with anti-DPTP10D MAbs, a strong 210-kDa DPTP10D band
was observed (lane 2). Control mouse IgG did not immuno-
precipitate either gp150 or DPTP10D from CNS or disc lysates
(lane 1). These data confirm our results with S2 cells and
demonstrate that gp150 and DPTP10D form complexes in a
native context in which neither the distribution nor the cellular
concentration of the proteins has been manipulated.
Since the cytoplasmic domain of gp150 includes four ty-
rosine residues, all within ITAM-like sequences, we next eval-
uated the phosphotyrosine content of native gp150 derived
from larval CNS and imaginal disc tissue. We probed immu-
noblots of gp150 immunoprecipitates with anti-phosphoty-
rosine MAbs and found that gp150 was phosphorylated in
lysates derived from wild-type larval CNS and imaginal disc
tissue (Fig. 2B, lane 2). Interestingly, gp150 tyrosine phosphor-
ylation levels were somewhat reduced in anti-gp150 immuno-
precipitates derived from fly larvae in which DPTP10D was
overexpressed in neurons (Fig. 2B, lane 1; see Materials and
Methods for details). Overexpression of DPTP10D in this line
did not alter gp150 expression levels or cause a global dephos-
phorylation of tyrosine-phosphorylated proteins in larval ly-
sates (data not shown). Control mouse IgG did not immuno-
precipitate phosphorylated gp150 from larval lysates (lane 3).
These data demonstrate that gp150 is tyrosine phosphorylated
in vivo and support the potential involvement of the gp150
ITAM-like sequences in downstream signaling pathways that
can be modulated by DPTP10D activity.
gp150 is inducibly phosphorylated in pervanadate-treated
S2 cells. To examine further the regulation of gp150 phosphor-
ylation levels, we next examined the phosphotyrosine content
of immunoprecipitated gp150myc isolated from transfected S2
cells that were exposed to reagents that are known to alter
cellular protein tyrosine phosphorylation levels. gp150myc was
not phosphorylated to a detectable level in untreated cells (Fig.
3, lane 1). Treating intact cells with sodium orthovanadate
(Na3VO4), H2O2, insulin, or a Ca
21 ionophore had no effect
on gp150myc tyrosine phosphorylation (lanes 2, 3, 5, and 7).
When the potent PTP inhibitor combination of Na3VO4 and
H2O2 (pervanadate) (11, 49) was added, however, phosphor-
ylation of gp150myc on tyrosine was observed (lanes 4 and 6).
The inducible phosphorylation of gp150myc in the presence of
pervanadate suggests that gp150 is a substrate for endogenous
S2 cell PTKs. The balance of PTK and PTP activities may be
shifted by the presence of pervanadate, allowing tyrosine-phos-
phorylated gp150myc to accumulate.
Two additional tyrosine-phosphorylated proteins with mo-
lecular masses of 40 and 60 kDa are seen on phosphotyrosine
blots of anti-gp150 immunoprecipitates (Fig. 3, lanes 4 and 6).
The 40-kDa phosphoprotein was detected in anti-myc immu-
noprecipitates derived from lysates of pervanadate-treated
cells (lanes 4 and 6). gp150 immunocomplexes also included a
faint 60-kDa phosphorylated band following treatment of the
cells with a combination of pervanadate and insulin (lane 6).
Neither the 40-kDa nor the 60-kDa phosphoprotein was rec-
ognized by anti-myc antibodies, indicating that they were not
carboxy-terminal gp150myc breakdown products (data not
shown). One interpretation of these data is that upon gp150
tyrosine phosphorylation, the 40- and 60-kDa proteins bind to
the phosphorylated ITAM-like motifs.
Dsrc mediates phosphorylation of gp150. We next evaluated
three Drosophila tyrosine kinases, Dsrc, Dabl, and Dfer, for
FIG. 2. gp150 is tyrosine phosphorylated and forms complexes with
DPTP10D in vivo. (A) Lysates from larval CNS and imaginal disc tissue were
immunoprecipitated with either anti-gp150 (a-gp150) (lane 2) or control IgG
(lane 1) antibodies and processed for immunoblotting with either anti-DPTP10D
(a-DPTP10D) (top) or a-gp150 (bottom) antibodies. Note that larval DPTP10D
was observed in anti-gp150 immunoprecipitates (ip) (lane 2) but not in control
IgG immunoprecipitates (lane 1). (B) Lysates from larval CNS or imaginal disc
tissue derived from wild-type larvae (lane 2) or from larvae in which DPTP10D
is overexpressed in neurons (lane 1) were immunoprecipitated with anti-gp150
antibodies and processed for immunoblotting with anti-phosphotyrosine (a-Y PE)
antibodies. Larval gp150 was phosphorylated on tyrosine residues (gp150-Y PE) in
vivo (lanes 1 and 2), and gp150 phosphotyrosine levels were reduced in
DPTP10D overexpression larvae (compare lanes 1 and 2). Phosphorylated gp150
was not observed in control IgG immunoprecipitates derived from wild-type
larval lysates (lane 3).
FIG. 3. gp150 can be tyrosine phosphorylated in S2 cells. Lysates from trans-
fected S2 cells expressing gp150myc were immunoprecipitated with anti-myc
(a-myc) antibodies and processed for immunoblotting with either anti-phospho-
tyrosine (a-Y PE) (top) or anti-myc (bottom) antibodies. Prior to lysis, cells were
either left untreated (lane 1) or treated with the indicated agents (lanes 2 to 7).
Note that a dramatic increase in gp150myc tyrosine phosphorylation was induced
following combined treatments with Na3VO4 and H2O2 (lane 4) and Na3VO4,
H2O2, and insulin (lane 6). Prominent 40-kDa (lanes 4 and 6) and faint 60-kDa
(lane 6) tyrosine-phosphorylated proteins coimmunoprecipitated with phosphor-
ylated gp150myc. The 60-kDa band is located just above the prominent immu-
noreactive band observed in all lanes, which is the ;50-kDa Ig heavy chain of the
immunoprecipitating anti-myc antibodies. gp150myc expression levels were not
affected by these cell treatments (bottom).
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their ability to induce gp150 phosphorylation by cotransfecting
S2 cells with expression plasmids encoding gp150myc and each
of these kinases (16). Anti-myc immunoprecipitates from cells
coexpressing gp150myc and each of these tyrosine kinases were
analyzed by probing immunoblots with anti-phosphotyrosine
MAbs. We found that only Dsrc kinase induced tyrosine phos-
phorylation of gp150myc (Fig. 4A, lane 3). Coexpression of
either Dabl or Dfer did not lead to phosphorylation of
gp150myc (compare lanes 1, 2, and 4). To demonstrate that the
three kinases were active in this system, we performed parallel
experiments with the known Dabl substrate Enabled (Ena
[16]). As previously shown (16), Ena immunoprecipitated from
such transfectants was heavily phosphorylated when Dabl plas-
mids were cotransfected, demonstrating that Dabl was ex-
pressed and active (Fig. 4B, lane 2). Coexpression of the Dsrc
or Dfer kinases also caused modest increases in Ena phospho-
tyrosine content (lanes 3 and 4). Thus, all three kinases were
catalytically active but only Dsrc could mediate gp150 phos-
phorylation.
Tyrosine-phosphorylated 60- and 40-kDa proteins were con-
sistently observed in anti-myc immunoprecipitates from cells
coexpressing gp150myc and Dsrc (Fig. 4A, lane 3), paralleling
the result observed with gp150 immunocomplexes derived
from cells treated with pervanadate and insulin (Fig. 3). The
intensity of the 60-kDa phosphorylated protein, however, was
much greater in Dsrc transfectants. This finding, together with
its electrophoretic mobility and the known ability of Dsrc to
autophosphorylate (23), suggested that the coprecipitating 60-
kDa phosphoprotein might be Dsrc. This suggestion is also
consistent with the presence of three potential src family SH2
domain recognition sites (YXXL/I [39]) in the cytoplasmic
domain of gp150. To address this issue, we probed immuno-
blots of anti-myc immunoprecipitates with rat antisera gener-
ated against Dsrc. As shown in Fig. 4C (lane 2), Dsrc coim-
munoprecipitated with gp150myc when the two proteins were
coexpressed in S2 cells. Dabl, which could be detected in im-
munoprecipitates by virtue of its tyrosine phosphorylation in
S2 cells (17), was not observed in anti-myc immunoprecipitates
from cells coexpressing gp150myc and Dabl (Fig. 4A, lane 2).
These data demonstrate that phosphorylation of and coimmu-
noprecipitation with gp150 are not common features of over-
expressed kinases in S2 cells. Furthermore, the presence of
Dsrc and 40-kDa phosphoproteins in gp150 complexes sug-
gests that these proteins may be components of a gp150 sig-
naling pathway.
DPTP10D and DPTP99A mediate dephosphorylation of
gp150myc in S2 cells. To determine whether phosphorylated
gp150 might function as a substrate for DPTP10D in intact
cells, we expressed gp150myc and Dsrc together with
DPTP10D in transfected S2 cells. To generate cells expressing
different levels of DPTP10D, we cotransfected different
amounts of DPTP10D expression vector together with fixed
amounts of both gp150myc and Dsrc expression vectors. As
determined by densitometric analysis of immunoblots probed
with anti-DPTP10D MAbs, when 0.05 to 5 mg of DPTP10D
expression vector was used per transfection, there was an ap-
proximately linear relationship between the amount of DNA
transfected and the levels of DPTP10D protein expressed in
total-cell lysates (data not shown).
We found that the phosphotyrosine levels of immunopre-
cipitated gp150myc were reduced in a dose-dependent manner
as the amount of cotransfected DPTP10D plasmid increased
(Fig. 5A, compare lane 2 with lanes 3 to 5). Maximal dephos-
phorylation of gp150myc was achieved in S2 cells transfected
with .0.25 mg of DPTP10D plasmid (lane 5 to 7). The de-
crease in the level of phosphorylated gp150myc was not due to
a decrease in expression of the gp150myc protein, since anti-
myc immunoprecipitates contained equal amounts of
gp150myc (Fig. 5A, bottom panel). These data, combined with
earlier results demonstrating that gp150 is an in vitro substrate
for DPTP10D (45), are consistent with the hypothesis that
gp150 is a direct target of DPTP10D catalysis. The intensities
of the coimmunoprecipitated Dsrc and 40-kDa phosphopro-
tein bands were also reduced when DPTP10D was coex-
pressed, suggesting that these proteins either were dephospho-
rylated by DPTP10D or had dissociated from gp150myc in a
phosphotyrosine-dependent manner (lanes 5 to 7).
We also investigated whether coexpression of the neural
RPTP DPTP99A, which does not stably associate with gp150,
could mediate the dephosphorylation of gp150myc and the
disappearance of Dsrc and the 40-kDa protein from the im-
munoprecipitates. Again, we transfected fixed amounts of
gp150myc and Dsrc expression vectors together with different
amounts of DPTP99A expression plasmid. As described above
for DPTP10D, when 0.5 to 10 mg of DPTP99A expression
vector was used per transfection, there was an approximately
FIG. 4. The tyrosine kinase Dsrc can phosphorylate and bind gp150myc. (A)
Lysates from transfected S2 cells expressing gp150myc alone (lane 1) or together
with Dabl (lane 2), Dsrc (lane 3), or Dfer (lane 4) were immunoprecipitated with
anti-myc (a-myc) antibodies and processed for immunoblotting with anti-phos-
photyrosine (a-Y PE) (top) or anti-myc (bottom) antibodies. Note that only Dsrc
phosphorylates gp150myc (compare lanes 2 to 4). Significantly, gp150myc-asso-
ciated 40- and 60-kDa phosphoproteins were also evident in the presence of Dsrc
(lane 3). gp150myc expression levels were not affected by coexpression of the
kinases (bottom). (B) Lysates from transfected S2 cells expressing Ena alone
(lane 1) or with Dabl (lane 2), Dsrc (lane 3), or Dfer (lane 4) were immunopre-
cipitated with anti-Ena antibodies and processed for immunoblotting with anti-
phosphotyrosine antibodies. As expected, Dabl mediated a dramatic increase in
Ena phosphotyrosine levels (lane 2). Both Dsrc (lane 3) and Dfer (lane 4)
induced Ena phosphorylation, although to a lesser degree. (C) Lysates from
transfected S2 cells expressing gp150myc alone (lane 1) or with Dsrc (lane 2)
were immunoprecipitated with anti-myc antibodies and processed for immuno-
blotting with anti-Dsrc (a-Dsrc) antibodies. The 60-kDa Dsrc kinase was ob-
served in gp150myc immunoprecipitates upon Dsrc coexpression (lane 2).
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linear relationship between the amount of DNA transfected
and the level of DPTP99A protein expressed (data not shown).
DPTP99A coexpression caused a reduction in the phosphoty-
rosine content of gp150myc and the coordinate disappearance
of the 40-kDa phosphoprotein band (Fig. 5B, lanes 3 to 5).
Phosphorylated Dsrc was more resistant than gp150 to
DPTP99A-mediated dephosphorylation, since higher levels of
DPTP99A driven by increasing amounts of transfected
DPTP99A plasmid were required to reduce its phosphoty-
rosine content substantially (Fig. 5B, compare Dsrc and gp150
bands in lanes 2, 3, and 5).
We also examined the effects of DPTP10D and DPTP99A
overexpression on the phosphotyrosine content of cellular pro-
teins in stably transfected S2 cell lines in which all cells express
the RPTP. Immunoblots of total-cell lysates from such trans-
fectants revealed that neither RPTP produced a global reduc-
tion in cellular phosphotyrosine levels (data not shown). An
example of a specific phosphorylated protein that was not
dephosphorylated by these RPTPs is the Dabl substrate Ena.
As shown in Fig. 5C (lanes 1 to 3), Ena phosphotyrosine levels
were not affected by coexpression of either DPTP10D or
DPTP99A. In summary, our data support the conclusions that
DPTP10D and DPTP99A display some specificity in their cat-
alytic activities and that gp150 can apparently function as a
substrate for DPTP10D and DPTP99A.
Like DPTP10D and DPTP99A, DPTP69D (43) is also neu-
ron specific in late embryos (9). Unlike the other two RPTPs,
however, DPTP69D is constitutively expressed in S2 cells.
DPTP69D does not stably associate with gp150 (data not
shown). To determine whether DPTP69D overexpression
might also mediate gp150 dephosphorylation, we transfected
fixed amounts of gp150myc and Dsrc expression vectors alone
or together with a DPTP69D expression plasmid. We were
able to achieve modest (three- to fivefold) overexpression of
DPTP69D when more than 10 mg of DPTP69D plasmid was
used for transfection (Fig. 6B). DPTP69D is proteolytically
cleaved to different extents in S2 cells and larvae (reference 9
and unpublished results), and the two major forms detected
are 160 and 116 kDa.
DPTP69D overexpression did not significantly reduce the
phosphotyrosine content of gp150 or alter the amount of phos-
phorylated Dsrc present in anti-myc immunoprecipitates (Fig.
6A, compare lanes 2 and 3). Overexpression of DPTP69D did,
however, produce dephosphorylation and/or dissociation of
the 40-kDa phosphoprotein (compare lanes 2 and 3). These
data suggest that gp150 phosphotyrosine residues are resistant
to DPTP69D activity even under conditions in which this
RPTP is overexpressed.
Differential effects of wild-type and mutant DPTP10D cata-
lytic domains on gp150 phosphorylation. To confirm that the
effect of DPTP10D coexpression on gp150 phosphorylation
requires catalytic activity, we evaluated the effect of coexpress-
ing the myc-tagged cytoplasmic domain (10Dwt) or the cata-
lytically inactive cytoplasmic domain [10D(C-S)] on gp150
phosphotyrosine levels. As shown in Fig. 7 (compare lanes 4
and 2), coexpression of 10Dwt eliminated phosphorylation of
gp150myc and caused the disappearance of phosphorylated
Dsrc and the 40-kDa protein from the complex. The effect of
10Dwt coexpression was comparable to that seen for full-
length DPTP10D (lanes 3 and 4), suggesting that the cytoplas-
mic domain was necessary and sufficient for the enzymatic
interaction. In contrast, coexpression of the catalytically inac-
tive 10D(C-S) mutant had only a small effect on gp150myc
phosphorylation levels and no effect on the associated phos-
phoproteins (lane 5). The small reduction in gp150myc phos-
phorylation levels observed upon coexpression of 10D(C-S)
could be due to substrate masking (for a review, see reference
28). Since 10D(C-S) binds well to gp150 (Fig. 1C), this inter-
action might mask gp150 sites normally phosphorylated by
PTKs, thereby reducing the overall levels of phosphorylated
gp150. These results demonstrate that a catalytically active
PTP domain is required for gp150 dephosphorylation by
DPTP10D.
DISCUSSION
We have begun to explore the downstream signaling path-
ways of Drosophila neural RPTPs by a biochemical approach.
In this study, we focus on the adhesion molecule-like gp150
protein, which binds to the cytoplasmic domain of DPTP10D
and is an in vitro substrate for its catalytic activity (45). There
are two species of gp150, with apparent molecular masses of
FIG. 5. DPTP10D and DPTP99A mediate dephosphorylation of gp150 in S2
cells. (A and B) Lysates from transfected S2 cells expressing gp150myc alone
(lane 1) or with Dsrc (lanes 2 to 7 in panel A; lanes 2 to 5 in panel B) were
immunoprecipitated with anti-myc (a-myc) antibodies and processed for immu-
noblotting with either anti-phosphotyrosine (a-Y PE) (A and B, top) or anti-myc
(A and B, bottom) antibodies. Note that the phosphotyrosine content of
gp150myc was reduced in a dose-dependent manner as the amount of cotrans-
fected 10D-pRM (0.05 mg [lane 3], 0.25 mg [lane 4], 0.5 mg [lane 5], 5 mg [lane
6], or 10 mg [lane 7]) (A) or 99A-pRM (0.5 mg [lane 3], 5 mg [lane 4], or 10 mg
[lane 5]) (B) increased. gp150myc expression levels were not affected by coex-
pression of either DPTP10D or DPTP99A (A and B, bottom). (C) Lysates from
transfected S2 cells expressing Ena and Dabl alone (lane 1) or with either
DPTP10D (lane 2) or DPTP99A (lane 3) were immunoprecipitated with anti-
Ena antibodies and processed for immunoblotting with anti-phosphotyrosine
antibodies. Expression of either RPTP did not appreciably alter Ena phospho-
tyrosine levels.
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150 and 180 kDa, that are expressed in Drosophila S2 cells (Fig.
1) and larvae (Fig. 2). The molecular mass of the larger species
(180 kDa) may reflect the presence of additional posttransla-
tional modifications that are absent from the smaller species.
In addition to a large extracellular domain which resembles
those of known adhesion molecules (19, 29, 33), gp150 has a
short cytoplasmic domain containing tyrosine motifs that re-
semble the SH2 domain-binding ITAM elements found in ver-
tebrate immunoreceptors. The presence of these ITAM-like
motifs suggests that gp150 could transmit signal(s) via interac-
tions between phosphotyrosine residues and signaling mole-
cules with SH2 domains. DPTP10D and other RPTPs could
modulate such a signaling pathway by dephosphorylating
gp150.
In this study, we have analyzed the physical and enzymatic
interactions of gp150 with other proteins, including RPTPs and
PTKs, to explore their intracellular signaling pathways. We
show that gp150 exists in a complex with DPTP10D in S2 cells
(Fig. 1) and in larval CNS and imaginal disc tissue (Fig. 2).
Moreover, the ability of the mutant 10D(C-S) protein to bind
stably to gp150 in S2 cells (Fig. 1) demonstrates that the cyto-
plasmic domain of DPTP10D is sufficient to confer binding.
The stable association of 10D(C-S) with gp150 is consistent
with results examining the binding properties of other PTPs in
which critical residues in their catalytic domains, including the
essential cysteine residue, have been mutated (for a review, see
reference 28). For example, analogously mutated PTP-
PEST(C231S) forms stable complexes with the PTP-PEST sub-
strate p130cas whereas wild-type PTP-PEST does not (15).
We have also investigated whether the ITAM-like motifs in
the cytoplasmic domain of gp150 could function analogously to
those of immunoreceptors. gp150 derived from wild-type larval
tissue contains phosphotyrosine (Fig. 2). In S2 cells, gp150
phosphorylation can be induced by treating the cells with per-
vanadate (Fig. 3) or upon coexpression of the Dsrc PTK (Fig.
4A). Coexpression of two other catalytically active PTKs, Dabl
and Dfer, did not mediate gp150 phosphorylation, demonstrat-
ing that gp150 is not indiscrimately phosphorylated by overex-
pressed tyrosine kinases (Fig. 4A). The phosphorylation of
gp150 following Dsrc coexpression is consistent with the pres-
ence of a sequence motif (I/V-Y-hydrophilic-hydrophilic-hy-
drophobic) in the gp150 cytoplasmic domain that matches sites
recognized and phosphorylated by src family tyrosine kinases
(39).
In addition to inducing gp150 phosphorylation, Dsrc coim-
munoprecipitates with gp150 (Fig. 4C). This is consistent with
the fact that three of the four tyrosine motifs in the gp150
cytoplasmic tail match the consensus recognition site
(YXXL/I) characterized for mammalian src family SH2 do-
mains (40). It is possible that the 60-kDa phosphoprotein ob-
served in gp150 immunoprecipitates derived from pervana-
date- and insulin-treated cells is also Dsrc. We could not,
however, detect endogenous Dsrc in gp150 immunoprecipi-
tates under these conditions (unpublished results), perhaps
due to the low level of endogenous Dsrc expression in S2 cells.
Although Dsrc can phosphorylate a variety of cellular proteins
FIG. 6. DPTP69D does not mediate gp150 dephosphorylation in S2 cells. (A)
Lysates from transfected S2 cells expressing gp150myc alone (lane 1) or with
Dsrc (lanes 2 and 3) were immunoprecipitated with anti-myc (a-myc) antibodies
and processed for immunoblotting with either anti-phosphotyrosine (a-Y PE)
(top) or anti-myc (bottom) antibodies. Note that the phosphotyrosine content of
gp150myc was not appreciably affected by cotransfection of 69D-pRM (10 mg;
lane 3). gp150myc expression levels were also not affected by coexpression of
DPTP69D (bottom). (B) Lysates from mock-transfected S2 cells (lane 1) or S2
cells transfected with DPTP69D plasmids (lane 2) were processed for immuno-
blotting with anti-DPTP69D (a-DPTP69D) antibodies. After transfection with
69D-pRM (10 mg), a three- to fivefold increase in the amount of DPTP69D in
cell lysates was observed.
FIG. 7. The catalytic domain of DPTP10D mediates dephosphorylation of
gp150. Lysates from transfected S2 cells expressing gp150myc alone (lane 1) or
with Dsrc (lanes 2 to 5) were immunoprecipitated with anti-myc (a-myc) anti-
bodies and then processed for immunoblotting with either anti-phosphotyrosine
(a-Y PE) (top) or anti-myc (bottom) antibodies. The expression of either the
DPTP10D cytoplasmic domain 10Dwt (lane 4) or DPTP10D (lane 3) caused
dephosphorylation of gp150myc and also led to the disappearance of the asso-
ciated Dsrc and 40-kDa phosphoprotein bands (top). In contrast, expression of
the catalytically inactive DPTP10D cytoplasmic domain 10D(C-S) led to only a
small decrease in gp150myc levels and no appreciable decrease in the phosphor-
ylation levels and/or association of Dsrc and the 40-kDa protein (lane 5).
gp150myc expression levels were not appreciably altered by coexpression of the
other proteins (bottom).
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(23), the ability of Dsrc to complex with and phosphorylate
gp150 supports the hypothesis that the catalytic interaction of
these proteins is specific.
Dephosphorylation of gp150 is induced in a concentration-
dependent manner by the neural RPTP DPTP10D (Fig. 5A).
The DPTP10D cytoplasmic domain protein 10Dwt, but not its
catalytically inactive derivative 10D(C-S), also facilitates the
dephosphorylation of gp150 (Fig. 7). Dephosphorylation of
gp150 can also be induced by another neural RPTP, DPTP99A
(Fig. 5B). Overexpression of either of these RPTPs does not,
however, facilitate a global reduction in cellular protein phos-
photyrosine levels (data not shown) or mediate the dephos-
phorylation of the Ena phosphoprotein (Fig. 5B). Moreover,
overexpression of another neural RPTP, DPTP69D, did not
mediate a decrease in gp150 phosphotyrosine levels or alter
the amount of phosphorylated and/or associated Dsrc (Fig. 6),
suggesting that DPTP69D may recognize a different spectrum
of substrates. In total, our data support the conclusions that
DPTP10D and DPTP99A discriminate among potential sub-
strates and that gp150 is not dephosphorylated by all RPTPs.
These results, together with earlier results from our laboratory
showing that DPTP10D can dephosphorylate gp150 in vitro
(45), support the hypothesis that gp150 is a direct target for
DPTP10D catalytic activity in S2 cells.
In addition to dephosphorylating gp150, both full-length
DPTP10D and its cytoplasmic domain 10Dwt induce the de-
phosphorylation and/or dissociation of the gp150-associated
phosphoproteins Dsrc and the unidentified 40-kDa protein
(Fig. 5A and 7). DPTP99A also mediates the disappearance of
the 40-kDa phosphoprotein and, to a lesser degree, that of
Dsrc (Fig. 5B). Conclusions about the differing substrate spec-
ificities of DPTP10D and DPTP99A cannot be drawn, how-
ever, since data on relative protein concentrations and sub-
strate kinetics of these proteins in S2 transfectants are lacking.
Several possible models, however, could explain the apparent
dephosphorylation of the three proteins that are detected in
gp150 immunoprecipitates. In the first model, all three phos-
phoproteins might be direct targets for DPTP10D and/or
DPTP99A. In the second model, gp150 might be the primary
target, and its dephosphorylation would facilitate the dissoci-
ation of Dsrc and the 40-kDa protein from the complex. In the
third model, the activating tyrosine residue on Dsrc (23) could
be the primary target, and its dephosphorylation would lead to
Dsrc inactivation. The activity of DPTP10D, DPTP99A, and/or
endogenous S2 cell PTPs would then lead to the dephosphor-
ylation of gp150 and/or the 40-kDa protein. Our results do not
unequivocally distinguish among these models. For DPTP99A,
however, the second and third models are less likely, because
concentrations of DPTP99A that are sufficient to mediate
complete gp150 dephosphorylation do not dramatically reduce
Dsrc phosphorylation (Fig. 5B).
Many studies have been performed to evaluate the substrate
specificities of PTPs in vitro and in vivo. “Classical” (tyrosine-
specific) PTPs often appear to be fairly promiscuous with re-
spect to catalytic substrates, but exceptions to this generaliza-
tion have been characterized, some of which are mentioned
below. Of note, the hematopoietic cell RPTP CD45 is known
to act on a limited spectrum of physiological substrates, includ-
ing members of the src family PTKs and the TCR z chain
(reviewed in reference 46). RPTPa also exhibits substrate
specificity in that it specifically dephosphorylates the negative
regulatory site of mammalian pp60c-src, thereby activating the
kinase (6, 10, 48). PTP-PEST exhibits a very high degree of
substrate specificity, selectively dephosphorylating the p130cas
protein (15). Substrate specificity may be imparted by several
characteristics of phosphatases, including the primary struc-
ture of the catalytic domain, intrinsic localization signals such
as SH2 domains, and intracellular colocalization with potential
substrates (reviewed in references 12 and 26).
In summary, we have initiated the biochemical dissection of
the downstream signaling pathways of gp150 and of the Dro-
sophila neural RPTPs. Under some circumstances, DPTP10D
and/or DPTP99A may regulate gp150 signaling by modifying
the interactions of gp150 with downstream signaling molecules
such as Dsrc and the 40-kDa phosphoprotein. Of note, in
addition to Dsrc and the 40-kDa phosphoprotein, gp150 im-
munocomplexes include the SH2 domain-containing signaling
molecules Dshc (21, 24) and Drk (30, 37; our unpublished
results). These findings suggest that these signaling proteins
may also be components of a putative gp150 signal transduc-
tion pathway(s) whose interactions may be modulated by
RPTP activity. Since the RPTPs appear to function primarily
in the control of axon guidance, gp150 might also play a role in
growth cone path-finding decisions.
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